NASDAQ:FULCFulcrum Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fulcrum Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $17.85 +0.78 (+4.57 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$17.32Now: $17.85▼$19.0050-Day Range$16.09MA: $18.91▼$22.0652-Week Range$4.37Now: $17.85▼$22.96Volume50,270 shsAverage Volume131,671 shsMarket Capitalization$417.15 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingFulcrum Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.75, Fulcrum Therapeutics has a potential upside of 49.9% from its current price of $17.85.Amount of Analyst CoverageFulcrum Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesFulcrum Therapeutics has received 41 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFulcrum Therapeutics has received 43 “underperform” votes. (Add your “underperform” vote.)Community SentimentFulcrum Therapeutics has received 51.19% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Fulcrum Therapeutics and other stocks. Vote “Outperform” if you believe FULC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FULC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFulcrum Therapeutics does not currently pay a dividend.Dividend GrowthFulcrum Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $358,763.00 in company stock.Percentage Held by InsidersOnly 30.30% of the stock of Fulcrum Therapeutics is held by insiders.Percentage Held by Institutions68.89% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($3.02) to ($3.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulcrum Therapeutics is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulcrum Therapeutics is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulcrum Therapeutics has a P/B Ratio of 4.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FULC Previous Symbol CUSIPN/A CIKN/A Webwww.fulcrumtx.com Phone617-651-8851Debt Debt-to-Equity RatioN/A Current Ratio5.95 Quick Ratio5.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.73 per share Price / Book4.79Profitability EPS (Most Recent Fiscal Year)($8.13) Net Income$-82,680,000.00 Net MarginsN/A Return on Equity-173.48% Return on Assets-66.55%Miscellaneous Employees62 Outstanding Shares23,370,000Market Cap$417.15 million Next Earnings Date8/24/2020 (Estimated) OptionableNot Optionable NASDAQ:FULC Rates by TradingView Receive FULC News and Ratings via Email Sign-up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Fulcrum Therapeutics (NASDAQ:FULC) Frequently Asked Questions How has Fulcrum Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Fulcrum Therapeutics' stock was trading at $11.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FULC shares have increased by 60.8% and is now trading at $17.85. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Fulcrum Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fulcrum Therapeutics. When is Fulcrum Therapeutics' next earnings date? Fulcrum Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 24th 2020. View our earnings forecast for Fulcrum Therapeutics. How were Fulcrum Therapeutics' earnings last quarter? Fulcrum Therapeutics (NASDAQ:FULC) issued its earnings results on Wednesday, May, 13th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.06. The company had revenue of $0.75 million for the quarter. View Fulcrum Therapeutics' earnings history. What price target have analysts set for FULC? 6 equities research analysts have issued 12-month price targets for Fulcrum Therapeutics' shares. Their forecasts range from $23.00 to $29.00. On average, they anticipate Fulcrum Therapeutics' share price to reach $26.75 in the next twelve months. This suggests a possible upside of 49.9% from the stock's current price. View analysts' price targets for Fulcrum Therapeutics. Has Fulcrum Therapeutics been receiving favorable news coverage? Headlines about FULC stock have trended negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fulcrum Therapeutics earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future. View the latest news about Fulcrum Therapeutics. Who are some of Fulcrum Therapeutics' key competitors? Some companies that are related to Fulcrum Therapeutics include Y-mAbs Therapeutics (YMAB), Zymeworks (ZYME), Ironwood Pharmaceuticals (IRWD), Zogenix (ZGNX), Intra-Cellular Therapies (ITCI), Epizyme (EPZM), Intercept Pharmaceuticals (ICPT), BELLUS Health (BLUSF), Mersana Therapeutics (MRSN), Cytokinetics (CYTK), MacroGenics (MGNX), Karyopharm Therapeutics (KPTI), Revance Therapeutics (RVNC), Akcea Therapeutics (AKCA) and ZEALAND PHARMA/S (ZEAL). View all competitors. What other stocks do shareholders of Fulcrum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include Alector (ALEC), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Energy Transfer LP Unit (ET), Gilead Sciences (GILD), Kadmon (KDMN), NVIDIA (NVDA), InVitae (NVTA), AbbVie (ABBV) and Aldeyra Therapeutics (ALDX). Who are Fulcrum Therapeutics' key executives? Fulcrum Therapeutics' management team includes the following people: Dr. Robert J. Gould, CEO, Pres & Director (Age 64)Peter G. Thomson, VP of Fin. & AccountingMr. Bryan E. Stuart, Chief Operating Officer (Age 43)Dr. Owen B. Wallace, Chief Scientific Officer (Age 50)Dr. Diego Cadavid, Sr. VP of Clinical Devel. (Age 53) When did Fulcrum Therapeutics IPO? (FULC) raised $76 million in an initial public offering on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO. What is Fulcrum Therapeutics' stock symbol? Fulcrum Therapeutics trades on the NASDAQ under the ticker symbol "FULC." How do I buy shares of Fulcrum Therapeutics? Shares of FULC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Fulcrum Therapeutics' stock price today? One share of FULC stock can currently be purchased for approximately $17.85. How big of a company is Fulcrum Therapeutics? Fulcrum Therapeutics has a market capitalization of $417.15 million. The company earns $-82,680,000.00 in net income (profit) each year or ($8.13) on an earnings per share basis. Fulcrum Therapeutics employs 62 workers across the globe. What is Fulcrum Therapeutics' official website? The official website for Fulcrum Therapeutics is www.fulcrumtx.com. How can I contact Fulcrum Therapeutics? Fulcrum Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-651-8851 or via email at [email protected] This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
